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Summary Creatinine kinase BB (CK-BB) is elevated in many tumours including those of the breast. We have
recently described a new, highly sensitive and specific method for measuring CK-BB, based on monoclonal
antibodies and time-resolved fluorometry. Using this method, we quantitated CK-BB in 172 breast tumour
cytosols and examined the associations between CK-BB and other clinicopathological variables and patient
survival. High CK-BB levels were seen more frequently in tumours from patients who were younger (age <50
years), patients who qualified for chemotherapy and patients with oestrogen receptor-positive tumours. No
association was seen between CK-BB and tumour stage, grade, size, histological type or the progesterone
receptor. In univariate analysis, the risk of relapse or death was higher in the group with tumours containing
high CK-BB levels but the difference did not reach statistical significance. In multivariate analysis, the risk of
death was statistically significantly higher in the high-CK-BB group. Analysis of subsets of patients revealed
that patients with oestrogen receptor-negative cancer have higher risk of death if their tumours contain high
levels of CK-BB. Our data suggest that, in general, CK-BB is associated with more aggressive tumours but its
value as a prognostic indicator is limited. CK-BB content of breast tumours may be more useful as an aid in
selecting therapy directed at inhibiting this enzyme activity and thus depriving tumour cells of their energy
source.
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Creatine kinase (CK,E.C.2.7.3.2), an enzyme catalysing the
reversible phosphorylation between creatine and ATP, plays
an important role in energy metabolism. High concentrations
of CK may emerge in cells with intensified cellular activities,
such as tumour cells, since these cells require high levels of
energy. CK is a dimeric molecule with two subunits, M and
B. There are three isoenzymes of CK, CK-BB, CK-MB and
CK-MM. These CK isoenzymes are present in varying
amounts in different tissues. CK-BB is mainly expressed in
brain, lung, intestine, bladder, uterus, breast, prostate and
placenta. CK-MM predominates in the skeletal muscle and
the cardiac muscle is the major location of CK-BB (Moss and
Henderson, 1994; Wallimann et al., 1992).
Owing to its close relationship with oestrogen, CK-BB has
drawn a lot of attention in breast cancer research. Animal
studies have shown enhanced transcription of CK-BB by
oestrogen (Walker and Kaye, 1981; Pentecost et al., 1990).
Cell culture experiments demonstrated increased CK-BB
levels in breast cancer cells after stimulation by oestrogen,
(Scambia et al., 1986a). Immunohistochemical studies of
primary breast cancer tissues indicated a strong staining for
CK-BB, which was highly associated with the presence of
oestrogen receptor (ER) in the tumour tissue (Scambia et al.,
1988). Preliminary clinical investigations found higher serum
CK-BB levels in patients with metastatic breast cancer than
in patients with cancer in remission (Thompson et al., 1980).
Higher levels of CK-BB were also found in the cerebrospinal
fluid of patients with breast cancer metastatic to the brain
(Bach et al., 1989).
Recently, we developed a new time-resolved immuno-
fluorometric assay for CK-BB. This method is based on two
monoclonal anti-CK-BB antibodies and is highly specific and
sensitive for the CK-BB isoenzyme (Zarghami et al., 1995).
Using this method, we demonstrated that cytosolic CK-BB
levels were significantly higher in breast cancer tissue than in
normal breast tissue. The presence of CK-BB in tumour
tissue was highly associated with the presence of the ER but
not with the presence of the progesterone receptor (PR). In
the present study we examine whether the CK-BB concentra-
tion in breast cancer cytosols is associated with other clinical
and pathological features of breast cancer as well as the
survival of breast cancer patients.
Materials and methods
Patients with breast cancer
Tumour tissue was collected from 172 primary breast cancer
patients aged between 25 and 91 years (median age 56 years).
These patients were diagnosed and/or treated in the
Department of Gynecologic Oncology, University of Turin,
between January 1988 and December 1991. They represented
70% of all new breast cancer cases seen at the department
during that time period. They were consecutive cases
collected under the condition that sufficient tissue remained
after pathological examination and receptor analysis. Patients
with bilateral lesions, Paget's disease of the breast, or
disseminated disease at the time of diagnosis or within 2
months after surgery, and patients who received only
palliative treatment were excluded from the study.
All patients in this study were treated with modified
mastectomy or conservative surgery plus post-surgical
irradiation of the breast. Axillary lymph nodes were
examined by pathologists for 163 patients; the mean number
of nodes examined was 15 +6 (one standard deviation).
Eleven patients did not undergo node dissection because they
were older than 75 years. The patients were followed-up
clinically every 3 months for the first 2 years after surgery,
every 6 months for the next 3 years and then annually.
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Patients were staged according to the International Union
Against Cancer post-surgical tumour-node-metastasis
(pTNM) classification (Spiessl et al., 1989). Tumour speci-
mens were histologically graded and typed based on criteria
previously described (Bloom and Richardson, 1957; Hopton
et al., 1989). The tumour size, recorded as the maximum
diameter of the fresh mastectomy specimen ranged from 0.7
to 6 cm with a median size of 2.4 cm.
Adjuvant tamoxifen treatment was given to node-positive
post-menopausal patients and adjuvant chemotherapy CMF
(cyclophosphamide -methotrexate -5 -fluorouracil, intrave-
nously) was given to node-positive premenopausal patients.
If there was no indication of relapse, node-negative patients
did not receive adjuvant treatment after surgery. None of the
patients received adjuvant therapy before surgery.
Cytosol extraction
Tissue specimens were snap frozen in liquid nitrogen
immediately after surgical removal and were stored at
-80°C until cytosol extraction. About 0.2 g of tumour
tissue was pulverised manually to a fine powder at -800C,
and the cells were lysed for 30 min on ice with 2 ml of lysis
buffer (50 mmol 1 Tris buffer, pH 8.0, containing 150 mmol
sodium chloride, 5 mmol EDTA, 10 g Nonidet NP-40
surfactant and 1 mmol phenylmethylsulphonyl fluoride 1`).
The lysate was centrifuged at 15 000 g at 4°C for 30 min and
the supernatant was collected for measurement of CK-BB
and total protein.
Measurement of CK-BB and other markers
CK-BB concentration in breast cancer cytosols was measured
in duplicate with a time-resolved immunofluorometric assay
described in detail elsewhere (Zarghami et al., 1995). The
assay has a limit of detection around 0.002 ng ml-' and a
measurement range to 10 ng ml-'; the within-run coefficient
of variation (CV) is 4-9% and the between run CV is 6-
12%. The assay has no cross-reactivity with CK-MM and a
minimal cross-reactivity (3%) with CK-BB. The assay uses
two monoclonal antibodies (OEM Concepts, Toms River,
NJ, USA) one of which was coated to white microtitre wells
and the other one was biotinylated. For detection, we used
streptavidin conjugated to alkaline phosphatase (ALP). The
ALP substrate was 5'-fluorosalicylphosphate which, upon
hydrolysis, forms highly fluorescent complexes with Tb3+ and
EDTA.
Total protein concentration in the tumour cytosols was
measured using a commercial kit based on the bicinchoninic
acid (BCA) method (Pierce Chemical, Rockford, IL, USA).
ERs and PRs were measured with the dextran-coated
charcoal (DCC) method (Thorphe et al., 1986, 1987) and
the results were grouped into receptor-positive and -negative
categories based on a cut-off value of 10 fmol mg-' total
protein.
Statistical analysis
CK-BB values were categorised into two groups, high and
low levels of CK-BB, using the median as a cut-off point.
Relationships between CK-BB levels and other clinicopatho-
logical variables, including patient's age, clinical stage,
histological grade and type, nodal status, tumour size, ER,
PR and adjuvant treatment, were analysed using the
contingency table and chi-square test. Associations between
CK-BB levels and patient survival (relapse-free survival and
overall survival) were evaluated using both the Kaplan-
Meier survival analysis method (Kaplan and Meier, 1958)
and the Cox proportional hazards regression model (Cox,
1972). Computer software SAS (SAS Institute, Cary, NC,
USA) and EGRET (Statistics and Epidemiology Research
Corporation, Seattle, WA, USA) were employed.
Results
Association between CK-BB and other clinicopathological
variables
A total of 172 tumour extracts were analysed for CK-BB.
CK-BB levels in tumour cytosols varied widely from 5 to
2857 ng of CK-BB per mg of total protein with a median of
116 ng mg-'. Table I describes the association between CK-
BB status and other clinical and pathological variables.
Cancers with high levels of CK-BB were found more
frequently in younger patients (<50 years) than in older
patients (42% vs 22%). The difference was statistically
significant (P<0.01).
Patients with high levels of CK-BB in their cancer were
more likely to receive chemotherapy or chemotherapy plus
tamoxifen than did those with low CK-BB in their cancer
(28% vs 12%, P=0.03). This observation suggests that
cancers with high CK-BB were more aggressive and, as a
result, more patients from this group qualified to receive
chemotherapy. However, when we examined the relationship
between CK-BB status and nodal status, a trend was seen
associating high CK-BB with positive nodal status only
(P=0.14). Clinical stage, histological grade or tumour size,
did not significantly associate with the CK-BB level in the
breast tumours (P>0.23 in all cases).
High CK-BB levels were associated with presence of the
ER but the difference did not reach statistical significance
(P=0.10). The PR does not seem to be associated with CK-
BB (P=0.25), in accordance with previous results (Zarghami
et al., 1995).
Most patients studied (70%) had ductal carcinomas. The
rest of the histological types observed were lobular (13%),
lobular in situ (2%), medullary (5%), papillary (2%), tubular
Table I Associations between CK-BB levels in breast tumour
cytosols and other clinicopathological variables
CK-BB, higha CK-BB, low
Variable Patients (%) Patients (%) P-value
Age (years)
< 50 36 (41.9) 19 (22.1)
>50 50 (58.1) 67 (77.9) <0.01
Clinical stage
I 41 (47.7) 36 (42.4)
II 38 (44.2) 43 (50.6)
II-IV 7 (8.1) 6 (7.0) 0.70
Nodal status
Negative 36 (43.4) 43 (55.1)
Positive 47 (56.6) 35 (44.9) 0.14
Tumour size (cm)
<1.5 14 (16.7) 10 (11.9)
>1.5 70 (83.3) 74 (88.1) 0.38
Histological type
Ductal 62 (72.1) 58 (67.4)
Others 24 (27.9) 28 (32.6) 0.51
Histological grade
I 28 (32.6) 39 (45.4)
II 40 (46.5) 32 (37.2)
III 18 (20.9) 15 (17.4) 0.23
ER statuP
Negative 23 (28.1) 34 (40.0)
Positive 59 (71.9) 51 (60.0) 0.10
PR statuS'
Negative 30 (37.0) 39 (45.9)
Positive 51 (63.0) 46 (54.1) 0.25
Adjuvant treatment
None 33 (38.4) 42 (48.8)
Tamoxifen 29 (33.7) 34 (39.5)
Chemoi
tamoxifen 24 (27.9) 10 (11.6) 0.03
Relapse
No 62 (72.1) 68 (79.1)
Yes 24 (27.9) 18 (20.9) 0.29
Death
No 70 (81.4) 75 (87.2)
Yes 16 (18.6) 11 (12.8) 0.30
aCK-BB> 116 ngmg-'; a median value. bCut_offof 10 fmol mg-'.Creatine kinase BB in breast cancer
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(2%), tubulolobular (3%), and other histological types (3%).
No substantial difference in CK-BB positivity rates was seen
between ductal carcinomas and all other types combined.
CK-BB levels and patient survival
The follow-up time of the 172 patients studied ranged from 7
to 67 months with a median of 33 months. During the course
of follow-up, 42 patients relapsed and 27 died. No significant
difference in CK-BB levels was seen between those patients
with recurrence and those without recurrence as well as those
who died or those who are still alive (Table I). However, the
patient group with low CK-BB levels in their tumours
demonstrated fewer relapses and fewer deaths than the
Table II The Cox proportional hazards regression analysis for
relapse-free and overall survival of breast cancer patients
CK-BB Relative risk 95% Cla P-value
Univariate analysisfor relapse-free survival'
Lowc 1.00
High 1.41 0.76-2.59 0.27
Multivariate analysis for relapse-free survivald,e
Low 1.00
High 1.63 0.78-3.40 0.12
Univariate analysisfor overall survival'
Low 1.00
High 1.90 0.84-4.30 0.12
Multivariate analysis for overall survivalde
Low 1.00
High 3.66 1.18-11.35 0.03
aConfidence interval. bA total of 172 patients in the analysis. cCK-
BB< 116 ng mg'; a median value. dA total of 151 patients in the
analysis. eAdjusted for age, clinical stage, nodal status, tumour size,
histological grade, histological type and ER and PR status.
patient group with high CK-BB levels. Table II presents the
relative risks (RRs) for relapse or death of patients whose
tumours contained high levels of CK-BB, in comparison with
patients whose tumours contained low levels of CK-BB.
Patients whose tumours were rich in CK-BB did not have a
significantly increased risk for relapse or death in the
univariate analysis. The risk for relapse remained similar
after adjusting for age, nodal status, clinical stage,
histological grade and type, tumour size and ER and PR
status. However, the risk for death was significantly higher
(RR=3.7, P=0.03) in CK-BB-positive patients when a
similar adjustment was implemented. In general, the RR for
relapse and death was higher in the group with high levels of
CK-BB but this trend did not reach statistical significance
except in the case of overall survival in the multivariate
analysis.
Overall and relapse-free survival curves for all patients are
shown in Figure 1. Patients with high CK-BB levels have
lower survival probability during the follow-up period, but
the differences were not substantial as also demonstrated by
the relative risk in the Cox regression analysis (Table II). The
P-values for the log-rank test are shown in Figure 1.
The discrepancy in the extent of the RR for death between
the univariate and multivariate analysis suggests that the
relationship between CK-BB and survival may be compli-
cated by some clinical or pathological variables. To examine
this possibility, we conducted overall survival analysis in
subgroups ofpatients categorised by their ER or nodal status
(Figure 2). The results indicate that a significant overall
survival difference between the high and low CK-BB groups
might be present in the patients with ER-negative cancer, but
not in those with ER-positive cancer. When the patients were
stratified according to nodal status, those with node-negative
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Figure 1 Disease-free (a) and overall survival (b) ofpatients with
breast cancer and high or low levels of CK-BB in their tumours.
The P-value of the log-rank test was not statistically significant.
Figure 2 (a) Overall survival of patients with breast cancer
whose tumours are ER-positive or -negative and contain either
high or low levels of CK-BB. (b) The same analysis but the
patients were stratified according to nodal status. The P-value for
the log-rank test was statistically significant (P=0.04) between
tumours that are ER(-) and have either low or high CK-BB
levels.
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tumours had better survival irrespective of the CK-BB status
of the tumour. The CK-BB status did not affect survival in
the node-positive group (Figure 2).
Discussion
High CK activity in cancers has been noticed for years. A
plausible explanation ofthis phenomenon is that tumour cells
with high capacity for growth and proliferation may require
large amounts of energy supply to maintain these cellular
activities. The elevation of CK serves to meet these
requirements. Two recent developments may further improve
our understanding of the role of CK in cancer. Kaddurah-
Daouk et al., (1990) found that proteins encoded by
oncogenes from adenovirus could enhance the transcription
ofthe CK-BB gene. Other investigators have demonstrated in
in vitro experiments that the growth of tumour cells could be
suppressed when the energy metabolism involving CK was
interrupted by replacing creatine, the normal substrate of
CK, with analogues that have much lower rates of
transporting energy than does creatine (Martin et al., 1994).
Although the mechanisms may be different, the suppressive
effect of creatine analogues on tumour growth is identical to
that of most routinely used chemotherapeutics.
The association between CK-BB and oestrogen was first
recognised in animal studies. It was noted that levels of some
proteins in the uterus of immature rats were increased
significantly after administration of oestrogen. The major
component of the oestrogen-induced proteins, called IP, was
found to be present abundantly in the rat brain and was later
identified to be CK-BB (Reiss and Kaye, 1981). Elevated CK-
BB, stimulated by oestrogen, was also observed in other
reproductive organs of rats (Malnick et al., 1983). It was
confirmed, bothinanimalandcellculturestudiesthatoestrogen
could up-regulate the production of CK-BB at its transcrip-
tional level (Walker and Kaye, 1981; Scambia et al., 1986a;
Pentecost et al., 1990). These findings led to the suggestion that
CK-BB might be used as a biochemical marker of oestrogen
action in oestrogen-related cancers like breast cancer.
CK-BB was found to be increased in the serum of breast
cancer patients. Furthermore, the CK-BB levels were even
higher in women with metastatic breast cancer (Thompson et
al., 1980; Rubery et al., 1982; Neri et al., 1988). This
phenomenon was also observed in cancers of the colon,
stomach, prostate and small-cell lung cancer (Arenas et al.,
1989; McGing et al., 1990).
The CK-BB concentration is higher in cancerous breast
tissue than in adjacent non-cancerous or normal breast tissue
(Tsung, 1983; Zarghami et al., 1995). High CK-BB levels in
breast tissue tend to occur in steroid hormone receptor-
positive cancer (Scambia et al., 1986b, 1988) but not all
published results agree (Kaye et al., 1986). We recently
reported that CK-BB is associated with the ER (Zarghami et
al., 1995). In this study, this association did not reach
statistical significance probably because of the smaller
number of patients in this study (172 vs 336) and the
different methods used for the receptor assays. In the
previous study, receptors were measured with immunoas-
says; in this study we used ligand-binding assays.
Most patients with ER-positive breast cancer are expected
to have a good prognosis. Only 20-30% of these patients
will develop recurrent or metastatic disease within 5 years
(McGuire and Clark, 1992). A strong oestrogen impact is
believed to be associated with the growth and aggressiveness
ofcertain types ofbreast cancer cells. Ifhigh levels ofCK-BB
are a sign (or consequence) of an intensive oestrogen
influence in the tissue, as suggested by the animal and cell
culture studies, then, a positive association between ER and
CK-BB may complicate our understanding of CK-BB in
relation to oestrogen because oestrogen and ER are two
factors that seem to have an opposite impact on the outcome
of breast cancer patients.
Relapse-free and overall survival of patients with high or
low CK-BB were similar when the clinical and pathological
features of the cancer were not considered. However, after
adjusting for these factors, the overall survival was
significantly different between high CK-BB and low CK-BB
patients. Almost four times higher risk for death was observed
for patients with high CK-BB cancer. This finding is not
unexpected if one considers that a high level of CK-BB is an
indication of a strong impact of oestrogen on the cancer cells.
Why does a survival difference associated with CK-BB
become evident after controlling for clinical and pathological
factors? Further analysis suggested that ER status might
obscure the observation in the univariate analysis. However,
the survival advantage attributed to the low CK-BB category
only existed in patients with ER-negative cancer. Owing to
the small number of patients involved in the analysis, this
finding needs further confirmation with larger patient groups.
Among the clinical and pathological features, age was the
only one substantially associated with CK-BB levels in the
cancer. The number ofpatients who were under the age of 50
was almost doubled in the high CK-BB group compared with
those in the low CK-BB group. Since no information is
available to indicate that CK-BB levels may vary with age in
normal tissue, we could not determine if this association is
specific for breast cancer.
Normally, CK activity in breast tissue is due mainly to the
CK-BB isoenzyme (70-90% of total activity). Only
occasionally could CK activity in the breast be attributed
mostly to CK-MM. According to our previous study
(Zarghami et al., 1995), this phenomenon occurred only in
two cases out of 336 patients whose tumour cytosols were
measured for both total CK and CK-BB. Therefore, our
results should not be distorted by the situation that high CK
activity is missed owing to contribution by CK-MM.
In summary, CK-BB levels in breast cancer are higher in
patients < 50 years and are not associated with other clinical
and pathological features, including clinical stage, nodal
status, histological type and grade and tumour size. There is
no significant difference in relapse-free survival between
patients with high CK-BB and low CK-BB cancer, but a
higher risk of death was observed in high CK-BB patients
when other features of the cancer were adjusted. This study
does not support the idea that CK-BB could be an efficient
prognostic marker for breast cancer. However, CK-BB might
be useful in the future to select patients who are more
suitable to receive treatment that targets the CK substrates,
to disrupt an energy metabolic pathway of tumour cells.
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